Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Gross Margin (2016 - 2025)

Historic Gross Margin for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 53.37%.

  • Protalix BioTherapeutics' Gross Margin changed 0.0% to 53.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.54%, marking a year-over-year increase of 216700.0%. This contributed to the annual value of 54.46% for FY2024, which is 104500.0% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Gross Margin of 53.37% as of Q3 2025, which was down 0.0% from 62.51% recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Gross Margin registered a high of 82.47% during Q2 2023, and its lowest value of 15.54% during Q4 2023.
  • Over the past 5 years, Protalix BioTherapeutics' median Gross Margin value was 53.37% (recorded in 2025), while the average stood at 52.67%.
  • Per our database at Business Quant, Protalix BioTherapeutics' Gross Margin plummeted by -569800bps in 2021 and then skyrocketed by 631200bps in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Gross Margin stood at 63.18% in 2021, then grew by 14bps to 72.18% in 2022, then tumbled by -78bps to 15.54% in 2023, then soared by 406bps to 78.67% in 2024, then crashed by -32bps to 53.37% in 2025.
  • Its Gross Margin stands at 53.37% for Q3 2025, versus 62.51% for Q2 2025 and 19.11% for Q1 2025.